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One pathway begins with the neuronal membrane receptor for advanced glycation end products (RAGE) that normally binds advanced glycation end products (AGE) and mediates normal aging processes in tissues. Evidence suggests that the gene that codes for RAGE is overexpressed in areas that degenerate in AD -the hippocampus and frontal lobe -and that this receptor binds A b strands ( 11 ) . This not only allows for amyloid aggregation but also stimulates an immune infl ammatory response. RAGE-A b interaction causes macrophage colony-stimulating factor to be released, which interacts with its complement receptor, c-fms, on microglial cells. This immune activation triggers many characteristics of AD pathology and leads to cytotoxicity of neurons ( 8 ) .
Although nonspecifi c immune infl ammatory responses have been investigated, specifi c immune processes have only recently been considered in dementia. Schenk and colleagues ( 12 ) showed near-complete prevention of A b deposition in a transgenic platelet-derived growth factor-driven human amyloid precursor protein mouse immunized with synthetic human A b . Subsequent studies have shown anti-A b autoantibodies present at low levels in blood plasma samples of an elderly population ( 13 ) . Other studies have shown circulating anti-A b immunoglobulins (IgGs) in periphery, although levels were not always specifi c to AD ( 14 , 15 ) .
Such results suggest potential immunotherapies for AD -if low levels of autoantibodies are present naturally, then passive immunization with similar antibodies directed at autoantigens characteristic of the disease probably will not be toxic. In support, Dodel and colleagues ( 16 ) showed a reduction in levels of A b in blood plasma and cerebrospinal fl uid samples in human AD patients after immunization with anti-A b IgG and associated improvements in cognitive abilities for a 6-month period. Active immunization using prime and booster aggregates of A b -42 also have shown slowing of cognitive decline as a function of levels of anti-A b antibodies ( 17 ) . The mechanism for interaction between degenerative processes in the brain and circulating IgGs could result from compromises in the integrity of the blood brain barrier (BBB) ( 18 ) via microtrauma, microvascular pathology, or local infl ammation ( 19 ) .
These studies indicate that A b may play a part in cognitive decline seen in AD and interacts with general and specifi c immune systems. Understanding specifi c immunity may be key to fi nding better therapies and diagnostic methods.
Existing diagnostic methods are limited and restricted to ex vivo techniques to diagnose AD on a biologic level. Current clinical diagnostic methods include behavioral and neuropsychological tests, neuroimaging, blood chemistry markers, and other disease-status rule-outs. However, a biologic substrate specifi c to the disease would be an ideal identifi er of AD brain pathology. Past potential biomarkers have been too expensive, invasive, and inconclusive ( 20 ) . However, recent studies by Zhang and Pardridge ( 18 ) and Bouras and colleagues ( 19 ) showing evidence for BBB permeability support the hypothesis that an immune reaction to AD pathology may be seen in circulating blood. Thus, a blood measure would be a good option for diagnosis.
This idea was supported in two studies. Mice immunized with a human neurofi lament-derived AGE unexpectedly developed antibodies directed against both A b and a RAGE peptide fragment ( 21 ) . Results suggested that RAGE-A b interaction was a catalyst for autoimmune responses and that immune activation may not just be general infl ammation observed by Yan and colleagues ( 8 ) , but may include the generation of specifi c antibodies. In a study comparing plasma levels of A b and RAGE IgGs with cognition in demented and healthy control participants, Mruthinti and colleagues ( 22 ) found that when an affi nity purifi cation method was used to determine antibody (IgG) titer values specifi c to RAGE or A b antigen molecules in blood, AD patients had signifi cantly higher endogenous levels of both IgGs than healthy controls of the same age. This indicates that IgGs specifi c to RAGE and A b may be of use as a diagnostic tool for AD. Low -molecular weight (LMW) 1-42 amino acid A b peptide fragments may be more damaging to cells than other high -molecular weight proteins. It has been shown that protein hydrolyzed into peptides resulted in a greater increase in cellular injury compared with an equivalent amount by weight of unhydrolyzed protein ( 23 ) . AGEs can also lead to enhanced formation of free radicals both directly through catalytic sites in their molecular structure and via stimulation of membrane-bound NAD(P) H oxidase through the RAGE receptor and depletion of cellular antioxidant systems ( 24 ) . LMW-AGEs are able to bind in a stable fashion with AGE receptors, and the predominant effecter of pathogenic receptors (such as RAGE) may be LMW-AGEs rather than AGE proteins ( 25 ) . The serum concentration of LMW-AGEs has been correlated with the severity of renal disease and with aging ( 23 , 26 ) .
This study examined the relationships between IgGs directed at both RAGE and A b and specifi c areas of cognition. Participants across levels of cognitive functioning were given a Clinical Dementia Rating (CDR) ( 27 ) , the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) ( 28 ) , and provided a blood sample. CDR and RBANS scores were used as standards of functional dementia with which concentrations of anti-RAGE and anti-A b IgGs in blood plasma were compared.
We hypothesized that participants with higher CDR scores would have higher levels of IgGs in their blood plasma titers. Participants with low RBANS scores in cognitive areas associated with cortical functioning, that is, language and memory, would have high levels of the target plasma IgGs. RBANS has been shown to differentiate between " cortical " and " subcortical " dementias ( 29 ) , and one hallmark of AD is degeneration in temporal and frontal cortical areas of the brain.
In order for anti-RAGE and anti-A b IgGs to be good markers of AD, they must also be unrelated to other possible confounding factors. As age is the largest predictor of AD ( 30 ) , this study examined whether participant age might account for any variance in IgG levels. Finally, circulating levels of total IgGs may confound fi ndings of specifi c IgGs, so we additionally examined this role.
Methods
Neurological Disorders Database Repository Database
The Neurological Disorders Database Repository (NDDR, Alzheimer ' s Research Center, Medical College of Georgia, Augusta, GA.) is an ongoing collaborative effort hosted by the Medical College of Georgia (MCG) that collects information useful for research of neurological disorders, focusing on AD. For each participant, the NDDR contains scores of cognitive functioning, functional measures, and biologic indices. Based on a clinical diagnosis, local physicians refer two groups of participants -patients with AD, and those with other neurological disorders. Healthy control participants are recruited for the database primarily from caretakers accompanying participants and through advertisement. All data in this study are drawn from this repository.
Participants and Procedures
This study drew from NDDR data for 118 participants between October 29, 2002, and February 28, 2006 . Because original diagnoses were based on physician report, participants ' data was broken down into fi ve groups of staging level of dementia based on the CDR Scale ( 27 ) . Participants were generally interviewed, assessed, and had blood draws on a single day. Participants underwent an in-depth clinical interview by a trained interviewer (R.F.S.), followed by cognitive testing. CDR scores were based on all available data including collateral report and physician and chart notes if available. The same interviewer conducted the clinical interview and cognitive testing for all participants in the database and reliably followed the same semistructured format specifi ed for each behavioral measure ( 31 , 32 ) .
Behavioral Measures
Clinical Dementia Rating Scale . -The CDR is an observation and data-driven procedure used in staging severity of dementia commonly used in studies of AD ( 27 ) . Patients are assessed based on six cognitive and functional domainsmemory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each category is rated on a 5-point scale of impairment: 0 = none; 0.5 = questionable; 1 = mild impairment; 2 = moderate impairment; and 3 = severe impairment. Impairment scores determine the CDR global score of overall dementia, memory being the primary category considered.
Repeatable battery for the assessment of neuropsychological status. -The RBANS is a brief, well-validated neurocognitive test of abnormal cognitive decline in older adults used with a variety of types of dementia ( 28 , 32 ) . It measures fi ve indices of cognitive functioning (Immediate memory, visiospatial/constructional skills, language, attention, and delayed memory) across 12 subtests and includes a global score. It has been used in previous studies comparing neurocognitive performance with disease biomarkers ( 33 , 34 ) .
RAGE and A b IgG Purifi cation From Plasma
Plasma (0.5 mL) IgG was purifi ed via a two-step purifi cation process involving initial ammonium sulfate precipitation, followed by protein-G isolation as described elsewhere ( 22 ) . Nonspecifi c total IgG was further purifi ed to isolate RAGE and A b -specifi c IgG fractions by passing through aminohexyl sepharose 4B beads (1 mg/mL) conjugated with either RAGE or A b 1-42 peptides. After eluting unbound IgGs with three washes of phosphate-buffered saline (PBS), bound antigen-specifi c IgG was eluted with Trisglycine-HCl (pH 2.8). The pH of the eluate was adjusted to 7.0 with Tris-HCl, dialyzed in PBS, concentrated, and assessed for fi nal protein content.
Quantifying Specifi c IgGs
RAGE peptide or A b 1-42 (1 m g/100 m L per well) was coated to electroimmunodiffusion/radioimmunoassay strip plates and incubated overnight at 4°C. Antigen was discarded, and wells were blocked with 200 m L of Tris-buffered saline + Tween 20 (TBST) in 0.2% gelatin for 1 hour. Affi nity-purifi ed anti -A b 1-42 or anti-RAGE IgG (10 m g) derived from AD or control participants was added to each well and incubated overnight at 4°C. After washing three times with TBST, 200 m L of donkey anti-human IgG(F(ab ¢ ) 2 )-horseradish peroxidase -conjugated secondary antibody (1:1000) was added and incubated for 2 hours at 37°C. Plates were washed three times with TBST followed by adding 200 m L of ready made tetramethylbenzedine substrate (Sigma -Aldrich, St. Louis, MO) for blue color development, which was stopped after 15 minutes by adding 0.2 M H 2 SO 4 . Absorbance was read at 450 nm providing the titer values used in this study. Each sample was run in triplicate.
Peptides
RAGE peptide was synthesized according to the sequence ( 35 ) DQNITARIGKPLVLNCKGAPKKPPQQLEWKLN representing the nucleotide and amino acid sequence of human RAGE. The peptide was synthesized by the Molecular Biology Central Core facility at MCG. A b 1-42 was purchased from Sigma-Aldrich. Stock solutions of the peptides were prepared in deionized water (100 m g/mL), and aliquots were stored at − 80°C.
Statistical Analysis
Data were analyzed using the Statistical Package for Social Sciences (SPSS 13.0 for Windows; SPSS, Chicago, Ill). Initially, partial correlation was performed to determine relationship strengths among RBANS scores of global cognitive ability, RBANS index scores, and concentrations of anti-RAGE and anti-A b IgG proteins in blood samples while controlling for age and total IgG level. Analyses of covariance (ANCOVAs) evaluated the direction of the relationships between the level of dementia, as defi ned by CDR stage, RBANS global scores, and the IgG levels. Multiple regression analyses evaluated the variance accounted for by CDR and RBANS overall performance for each IgG. Finally, multiple regression was used to examine the different domains of cognition measured by the RBANS. For each IgG, RBANS index scores -immediate memory, visiospatial/constructional skills, language, attention, and delayed memory -were entered simultaneously as possible predictors of IgG levels. Throughout regression analyses, age and total IgG level were entered into the equations fi rst.
Results
Descriptive statistics for the total participant pool are presented in Table 1 . Partial correlational analyses controlling for age and total IgG level indicated that CDR global score was positively related to both RAGE and A b IgG levels. Similarly, RBANS global score was negatively correlated with both IgGs ( Table 2 ) .
ANCOVAs were used to provide support for the positive relationship between the CDR measure of dementia and IgG levels in blood plasma, as well as to rule out patient age and total IgG level as covariates. For anti-RAGE IgG, age did not account for a signifi cant portion of the variance ( F (1,106) = 0.38, p > .05). Total IgG level did account for a signifi cant amount of variance ( F (1,106) = 25.17, p < .001). However, CDR stage additionally accounted for a large portion of the variance ( F (4,106) = 12.93, p < .001) beyond that of total IgG level. For anti-A b , the results were similar, age lacking signifi cance ( F (1,106) = .001, p >.05), total IgG signifi cant ( F (1,106) = 25.17, p < .001), and CDR stage significantly predictive of additional variance after controlling for age and total IgG level ( F (4,106) = 17.08, p < .001). Figure 1 illustrates levels of anti-RAGE and anti-A b IgGs across increasing CDR stages of dementia.
Multiple regression analysis was performed to determine the portion of variance in CDR scores accounted for by anti-RAGE or anti-A b IgGs over and above that of total IgG levels. As the fi rst step in the model, total IgG accounted for nearly 13% of the variance in CDR rating. Anti-RAGE or anti-A b IgGs explained an additional 39% of the variance ( R 2 change; Table 3 ). Concentration levels of anti-A b and anti-RAGE IgGs were pitted against each other as possible predictors of CDR global scores. When the two IgGs competed for variance, anti-A b remained a signifi cant predictor ( t = 3.17, p < .01). Anti-RAGE IgG lost signifi cance as the second variable in the regression ( t = 1.70, p = .09). The unexpected change in the coeffi cient for this variable suggests multicollinearity for anti-RAGE and anti-A b IgGs as predictors of CDR score variance. Similarly, multiple regression analysis was performed to determine the variance in RBANS total scores accounted for by anti-RAGE or anti-A b IgG over and above that of total IgG levels. Total IgG accounted for nearly 15% of the variance in RBANS total scale score, and IgG markers explained an additional 23% of the variance ( R 2 change; Table 4 ). When anti-A b and anti-RAGE IgGs competed for the variance, anti-A b Note : RBANS = repeatable battery for the assessment of neuropsychological status; RBANS index scores: ImMem = immediate memory; DelMem = delayed memory; VisoCons = visuo-constructional skills. A b = amyloid-beta; CDR = clinical dementia rating; IgG = IG = immunoglobulin. We used index scores from the RBANS to assess the relationship between IgG concentrations and specifi c domains of cognition to show that anti-RAGE and anti-A b IgGs are specifi c to dementia that matches an Alzheimertype profi le. Taken together, RBANS index scores accounted for nearly 24% and 25% of variance in anti-RAGE IgGs and anti-A b IgGs after controlling for total IgG, respectively (see R 2 change scores; Tables 5 and 6 ). Simultaneous regression confi rmed the hypothesis that defi cits in language and delayed memory, which are associated with temporal and frontal lobe cortical function, would predict high levels of RAGE-and A b -directed antibodies more strongly than cognitive skills associated with subcortical brain activity ( 29 ) .
The Language Index of the RBANS was negatively and signifi cantly predictive of each IgG. The Delayed Memory Index was signifi cantly predictive of anti-RAGE IgG levels. No other index scores approached signifi cance for either IgG.
Discussion
Results of this study begin to clarify the role of specifi c immune responses in AD and point to IgGs directed against RAGE and A b as potential biomarkers for the disease. RAGE and A b IgGs were both signifi cantly correlated with CDR stage as well as with RBANS global score. These fi ndings were consistently shown above and beyond the effects of both age and total IgG level. This shows a strong relationship between the biomarkers and declines in cognition. Furthermore, ANCOVA showed a signifi cant between-groups difference across CDR stages, even when controlling for age and total IgG effects, further supporting the hypothesis that dementia levels are signifi cantly associated with IgG levels across the sample, for both anti-RAGE and anti-A b IgG. A point of caution should be noted, however, as it cannot defi nitively be ruled out that our fi ndings of increased IgG elevations and CDR stage could include a nonspecifi c state of heightened autoimmunity in patients with AD, as evidence of such autoimmunity Note : A b = amyloid-beta; IG = immunoglobulin; RAGE = receptor for advanced glycation end products; SE = standard error.
remained a signifi cant predictor ( t = 2.16, p < .05), whereas anti-RAGE IgG lost signifi cance as the second variable in the regression ( t = 0.92, p > .05). Note : IG = immunoglobulin; RAGE = receptor for advanced glycation end products; RBANS = repeatable battery for the assessment of neuropsychological status; SE = standard error. Note : A b = amyloid-beta; IG = immunoglobulin; RAGE = receptor for advanced glycation end products; RBANS = repeatable battery for the assessment of neuropsychological status; SE = standard error.
changes have been previously reported to occur with advancing age ( 4 ) .
Of interest is the fact that anti-A b outcompeted anti-RAGE for the variance in CDR global scores and RBANS total score when these IgGs were regressed against each other. This suggests that each IgG has a very similar underlying relationship with the construct of dementia, as well as with variance in cognitive performance. These results make sense in light of previous studies showing RAGE and A b as closely related in the brain pathology of AD ( 36 ) .
As predicted, regression showed that both biomarkers were signifi cantly related to RBANS index scores in cortical areas of cognition -Language, and in the case of anti-A b , delayed memory. This provides some support for the hypothesis that these IgGs may specifi cally mark cortical forms of dementia like AD and have the potential for distinguishing them from subcortical forms such as Parkinson's disease.
A limitation of this study is the fact that it ignored diagnoses of diabetes, which has an amyloid component and may infl uence levels of circulating anti-A b IgG ( 37 ) . Additionally, the numbers of participants in the Mild Cognitive Impairment and Moderate/Severe CDR groups were comparatively lower, although many participants were included overall. Further studies will benefi t from our continued efforts to add to the NDDR and will focus on similar analyses for a more homogenous sample of only MCI patients.
Theories of AD development also point to avenues of possible investigation. The amyloid cascade hypothesis conjectures that the AD process begins as A b peptides are fi rst deposited in preamyloid lesions (diffuse plaques) ( 6 ) . However, these have been found extensively in aged persons with no clinical symptoms ( 38 ) . Although such fi ndings could support the idea that amyloid deposition may not be specifi c to AD at all, they could alternatively be interpreted to support the idea that AD could be detected with a biomarker of amyloid lesions long before development of symptoms. A longitudinal study examining cognitive symptoms of participants over time, especially in the high -AD risk group of MCI patients, will help to clarify this issue. Examining changes in cognitive abilities and levels of IgGs for a period of time will allow observation of the relationship across the progression of the disease.
Finally, the results of this study may point to new treatment venues. One study examined passive immune response to A b IgG immunization, fi nding actual improvements in cognitive functioning ( 16 ) . Although RAGE would probably not be a good candidate for active immunization treatments, anti-RAGE IgG could feasibly be used in a passive immunization serum. As the current study has pointed to a relationship between RAGE-specifi c immune processes and cognitive decline, it would be interesting to investigate a treatment of this sort. 
